GlassScriptPhysician profile
Donald C Haas
NPI 1205876406
$36,904.00
in general payments reported to CMS, 2019-2025
20 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,049 · 2020: $4,495 · 2021: $12K · 2022: $5,367 · 2023: $8,554 · 2024: $2,887 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,363 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,275 · Food and Beverage: $995 · Travel and Lodging: $69.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,362.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,275.00 |
| Food and Beverage | $994.70 |
| Travel and Lodging | $69.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19,026.20 | 2019-2025 | |
| Abbott Laboratories | $17,608.42 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Xience Sierra |
| E.R. Squibb & Sons, L.L.C. | $87.39 | 2024-2025 | Camzyos |
| Akcea Therapeutics, INC. | $41.97 | 2019 | |
| Kestra Medical Technology Services, INC. | $35.07 | 2024 | Assure Wcd |
| Edwards Lifesciences Corporation | $22.39 | 2023 | |
| Atricure, INC. | $18.61 | 2020 | |
| Novartis Pharmaceuticals Corporation | $18.19 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $15.69 | 2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.65 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.42 | 2023 | Amvuttra |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Haas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.